200. Clinical trial of metformin to treat preterm preeclampsia: pharmacokinetics and biomarker studies

Abstract

Introduction Metformin is a potential therapeutic for preeclampsia as it decreases sFlt-1 and soluble endoglin and rescues endothelial dysfunction. Metformin pharmacokinetics in preeclampsia, where there is increased renal clearance and proteinuria, has not been established. Objective/Hypothesis To evaluate metformin XR (extended release) pharmacokinetics in preterm preeclampsia, obtain data on pregnancy prolongation and circulating levels of biomarkers associated with endothelial dysfunction. Methods 15 women with preterm preeclampsia were treated with 1.5 g metformin XR twice daily. Pharmacokinetic sampling was performed on day 1 at 2,4,5,6,7,8,24 h, and concentrations measured using liqui..